nccit cell line Search Results


teratocarcinoma cell line nccit  (Grobet Inc)
90
Grobet Inc teratocarcinoma cell line nccit
Teratocarcinoma Cell Line Nccit, supplied by Grobet Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/teratocarcinoma cell line nccit/product/Grobet Inc
Average 90 stars, based on 1 article reviews
teratocarcinoma cell line nccit - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
nccit cell line  (Lonza)
90
Lonza nccit cell line
Nccit Cell Line, supplied by Lonza, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/nccit cell line/product/Lonza
Average 90 stars, based on 1 article reviews
nccit cell line - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
nccit cell line  (GenScript corporation)
90
GenScript corporation nccit cell line
Knockdown of VIRMA attenuates the malignant phenotype and enhances sensitivity <t>to</t> <t>cisplatin</t> in vitro. A : CRISPR/Cas9-mediated knockdown of VIRMA in <t>NCCIT</t> cells (~ 50% reduction), leading to decreased protein expression of other members of the writer complex – METTL3, WTAP and METTL14. Results are normalized to ß-actin and expressed as fold-change compared to scramble condition; B : Relative levels of m 6 A, expressed as fold-change compared to scramble condition, both by ELISA kit (top) and dot blot (bottom, normalized to methylene blue); C – Illustration of the m 6 A writer complex and hypothesis related to its disruption upon VIRMA knockdown; D – Tumor cell growth curves in VIRMA knockdown cells compared to scramble condition along 72 h; E – Measurement of tumor cell proliferation by BrdU assay along 72 h. Results are expressed as fold-change compared to scramble condition; F – Measurement of migration capacity. Results are expressed as fold-change compared to scramble condition; G - Measurement of invasion capacity. Results are expressed as fold-change compared to scramble condition; H – Cell viability curves for NCCIT-VIRMA knockdown and scramble cells treated with cisplatin. Results are expressed as percentage cells surviving, normalized to the vehicle. IC 50 concentration is indicated for each condition. * p < 0.05; ** p < 0.01; **** p < 0.0001
Nccit Cell Line, supplied by GenScript corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/nccit cell line/product/GenScript corporation
Average 90 stars, based on 1 article reviews
nccit cell line - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
nccit cell line  (JCRB Cell Bank)
90
JCRB Cell Bank nccit cell line
Knockdown of VIRMA attenuates the malignant phenotype and enhances sensitivity <t>to</t> <t>cisplatin</t> in vitro. A : CRISPR/Cas9-mediated knockdown of VIRMA in <t>NCCIT</t> cells (~ 50% reduction), leading to decreased protein expression of other members of the writer complex – METTL3, WTAP and METTL14. Results are normalized to ß-actin and expressed as fold-change compared to scramble condition; B : Relative levels of m 6 A, expressed as fold-change compared to scramble condition, both by ELISA kit (top) and dot blot (bottom, normalized to methylene blue); C – Illustration of the m 6 A writer complex and hypothesis related to its disruption upon VIRMA knockdown; D – Tumor cell growth curves in VIRMA knockdown cells compared to scramble condition along 72 h; E – Measurement of tumor cell proliferation by BrdU assay along 72 h. Results are expressed as fold-change compared to scramble condition; F – Measurement of migration capacity. Results are expressed as fold-change compared to scramble condition; G - Measurement of invasion capacity. Results are expressed as fold-change compared to scramble condition; H – Cell viability curves for NCCIT-VIRMA knockdown and scramble cells treated with cisplatin. Results are expressed as percentage cells surviving, normalized to the vehicle. IC 50 concentration is indicated for each condition. * p < 0.05; ** p < 0.01; **** p < 0.0001
Nccit Cell Line, supplied by JCRB Cell Bank, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/nccit cell line/product/JCRB Cell Bank
Average 90 stars, based on 1 article reviews
nccit cell line - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

Image Search Results


Knockdown of VIRMA attenuates the malignant phenotype and enhances sensitivity to cisplatin in vitro. A : CRISPR/Cas9-mediated knockdown of VIRMA in NCCIT cells (~ 50% reduction), leading to decreased protein expression of other members of the writer complex – METTL3, WTAP and METTL14. Results are normalized to ß-actin and expressed as fold-change compared to scramble condition; B : Relative levels of m 6 A, expressed as fold-change compared to scramble condition, both by ELISA kit (top) and dot blot (bottom, normalized to methylene blue); C – Illustration of the m 6 A writer complex and hypothesis related to its disruption upon VIRMA knockdown; D – Tumor cell growth curves in VIRMA knockdown cells compared to scramble condition along 72 h; E – Measurement of tumor cell proliferation by BrdU assay along 72 h. Results are expressed as fold-change compared to scramble condition; F – Measurement of migration capacity. Results are expressed as fold-change compared to scramble condition; G - Measurement of invasion capacity. Results are expressed as fold-change compared to scramble condition; H – Cell viability curves for NCCIT-VIRMA knockdown and scramble cells treated with cisplatin. Results are expressed as percentage cells surviving, normalized to the vehicle. IC 50 concentration is indicated for each condition. * p < 0.05; ** p < 0.01; **** p < 0.0001

Journal: Journal of Experimental & Clinical Cancer Research : CR

Article Title: The component of the m 6 A writer complex VIRMA is implicated in aggressive tumor phenotype, DNA damage response and cisplatin resistance in germ cell tumors

doi: 10.1186/s13046-021-02072-9

Figure Lengend Snippet: Knockdown of VIRMA attenuates the malignant phenotype and enhances sensitivity to cisplatin in vitro. A : CRISPR/Cas9-mediated knockdown of VIRMA in NCCIT cells (~ 50% reduction), leading to decreased protein expression of other members of the writer complex – METTL3, WTAP and METTL14. Results are normalized to ß-actin and expressed as fold-change compared to scramble condition; B : Relative levels of m 6 A, expressed as fold-change compared to scramble condition, both by ELISA kit (top) and dot blot (bottom, normalized to methylene blue); C – Illustration of the m 6 A writer complex and hypothesis related to its disruption upon VIRMA knockdown; D – Tumor cell growth curves in VIRMA knockdown cells compared to scramble condition along 72 h; E – Measurement of tumor cell proliferation by BrdU assay along 72 h. Results are expressed as fold-change compared to scramble condition; F – Measurement of migration capacity. Results are expressed as fold-change compared to scramble condition; G - Measurement of invasion capacity. Results are expressed as fold-change compared to scramble condition; H – Cell viability curves for NCCIT-VIRMA knockdown and scramble cells treated with cisplatin. Results are expressed as percentage cells surviving, normalized to the vehicle. IC 50 concentration is indicated for each condition. * p < 0.05; ** p < 0.01; **** p < 0.0001

Article Snippet: NCCIT cell line (the one showing the highest resistance to cisplatin compared to 2102Ep and NT2, as documented in our previous study [ ]) was chosen to perform VIRMA knockdown by plasmids carrying the CRISPR/Cas9 system containing a guide RNA sequence (available in [ ]) targeting this gene (obtained from GenScript, Piscataway, NJ).

Techniques: Knockdown, In Vitro, CRISPR, Expressing, Enzyme-linked Immunosorbent Assay, Dot Blot, Disruption, BrdU Staining, Migration, Concentration Assay